M.DI CROHN PERIANALE FISTOLIZZANTE: USTEKINUMAB E’ ATTIVO. UNA REVIEW DA “Drugs in R&D ” (FREE)

ENDOSCOPIA, GASTROENTEROLOGIA, IBD, NEWSLETTER

Nella malattia di Crohn perianale fistolizzante, Ustekinumab mostra un segnale di attività clinica interessante, confermando un possibile ruolo nelle forme complesse e refrattarie, dove il controllo dell’infiammazione e la gestione della fistola restano sfide aperte. La review su Drugs in R&D rafforza l’idea che l’asse IL-12/23 possa rappresentare un’opzione terapeutica utile soprattutto nei pazienti con…

OH ! LA ATTIVITA’ FISICA RIDUCE LA MORTALITA’ PER CANCRO DEL 26%! UNA GRANDE META-ANALISI SU 3200 PAZIENTI DELL’APRILE 2026 DA “Cancer Treat Rev” (FREE)

GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, NEWSLETTER, ONCOLOGIA, Senza categoria

Physical activity reduces all-cause mortality in patients with cancer: a systematic review and meta-analysis of randomized controlled trials Hugo Guillermou ET AL. Abstract Introduction: Growing evidence suggests that physical activity (PA) may improve survival in patients with cancer. However, causal evidence from randomized controlled trials (RCTs) remains limited. This systematic review and meta-analysis aims to evaluate…

PREVENZIONE DEL DANNO DA FANS: ARRIVA LA REBAMIPIDE! LA PRIMA REVISIONE SISTEMATICA CON META-ANALISI. DA “American Journal of Gastroenterology”

GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, NEWSLETTER

Efficacy of Rebamipide in the Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Mucosal Breaks: A Systematic Review and Meta-Analysis Cion, Rochelle Ivy A. MD; Juyad, Ian Gabriel A. MD; Yasay, Eric B. MD INTRODUCTION: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most used medications worldwide. A major limitation of these drugs is gastrointestinal (GI) mucosal injury. Several…

COME POTREBBERO FUNZIONARE I VACCINI A BASE mRNA PER LA TERAPIA DEL CANCRO? UNA GRANDE ANALISI DA RITA RUBIN. DA “JAMA” (FREE)

CHIRURGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, INTERNATIONAL SNAPSHOTS, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI

How mRNA Vaccines Could Help Treat Cancer Rita Rubin, MA Malignant tumors are sneaky. They tend to fly under the immune system’s radar because, unlike invaders such as viruses or bacteria, cancer cells arise from normal cells, so they bear many of the same familiar molecules on their surface. (opens in new tab) Once tumors…

COLITE ULCEROSA: COSA FARE SE VEDOLIZUMAB NON FUNZIONA? UN OTTIMO STUDIO DI COORTE DA “GETAID” SULLA SECONDA LINEA DI TRATTAMENTO. DA “UEG JOURNAL” (FREE)

GASTROENTEROLOGIA, IBD, METODOLOGIA, NEWSLETTER

Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID Louis Calméjane et al for GETAID ABSTRACT Background and Aims Vedolizumab has become the preferred first-line advanced therapy in ulcerative colitis (UC). However, the optimal second-line treatment following vedolizumab failure remains unclear. We aimed to evaluate…

EHILA’! QUALCHE CONSIGLIO PER LEGGERE VELOCEMENTE UN NUOVO TRIAL? LASCIATE PARLARE BISHAL GYAWALI! ARTICOLO MONSTRE! DA”JCO ONCOLOGY PRACTICE” (FREE)

GASTROENTEROLOGIA, METODOLOGIA, NEWSLETTER, ONCOLOGIA

How I Read a Clinical Trial Report? A Primer for Busy Clinicians  Bishal Gyawali, MD, PhD, FASCO  Reading a clinical trial report with a critical lens requires some skills and training. Unfortunately, these skills are not often taught during residency or fellowship. In this study, I will discuss my approach to critical appraisal of a cancer clinical…